Anticoagulation Market: Information by Drug Class (Novel and Direct Anticoagulants [DOACs], Heparin and Low Molecular Weight [LMWH], Warfarin, Vitamin K Antagonists), Disease Indication(Anti Fibrillation [A-Fib], Stroke, Deep Vein Thrombosis/Pulmonary Embolism [PE], Mechanical Heart Valves [MHV]), Route of Administration (Oral and Injectable), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2030
ID: MRFR/HC/9168-CR | 145 Pages | Published By Rahul Gotadki on August 2021
LIST OF CONTENTS
1 EXECUTIVE SUMMARY 14
2 MARKET INTRODUCTION 15
2.1 DEFINITION 15
2.2 SCOPE OF THE STUDY 15
2.3 RESEARCH OBJECTIVE 15
2.4 MARKET STRUCTURE 15
2.5 ASSUMPTIONS & LIMITATIONS 16
3 RESEARCH METHODOLOGY 17
3.1 DATA MINING 17
3.2 SECONDARY RESEARCH 18
3.3 PRIMARY RESEARCH 18
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19
3.5 FORECASTING TECHNIQUES 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
3.6.1 BOTTOM-UP APPROACH 22
3.6.2 TOP-DOWN APPROACH 22
3.7 DATA TRIANGULATION 23
3.8 VALIDATION 23
4 MARKET DYNAMICS 24
4.1 OVERVIEW 24
4.2 DRIVERS 25
4.2.1 RISING INCIDENCE OF CARDIOVASCULAR AND CORONARY ARTERY DISEASES 25
4.2.2 GROWING AWARENESS, EXPENDITURE, AND DEPENDENCE ON ANTICOAGULANTS 25
4.3 RESTRAINTS 26
4.3.1 STRINGENT REGULATORY NORMS 26
4.4 OPPORTUNITIES 27
4.4.1 INCREASING PATIENT POPULATION AND PATENT EXPIRY TO SUPPORT NEW PRODUCT LAUNCH 27
5 MARKET FACTOR ANALYSIS 28
5.1 VALUE CHAIN ANALYSIS 28
5.1.1 R&D 29
5.1.2 MANUFACTURING 29
5.1.3 DISTRIBUTION AND SALES 29
5.1.4 POST-SALES MONITORING 29
5.2 PORTER'S FIVE FORCES MODEL 29
5.2.1 BARGAINING POWER OF SUPPLIERS 30
5.2.2 BARGAINING POWER OF BUYERS 30
5.2.3 THREAT OF NEW ENTRANTS 30
5.2.4 THREAT OF SUBSTITUTES 31
5.2.5 INTENSITY OF RIVALRY 31
5.2.6 US AND GLOBAL NUMBER OF PATIENTS ON ANTICOAGULANTS (2019), IN MILLION 31
5.3 IMPACT OF COVID-19 ON THE ANTICOAGULATION MARKET 32
5.3.1 OVERVIEW 32
5.3.2 IMPACT ON SUPPLY CHAIN 32
5.3.3 IMPACT ON DEMAND FOR ANTICOAGULATION DRUGS 32
5.3.4 EFFECT 0F ANTICOAGULATION ON COVID-19 PATIENTS 33
5.4 PATENT EXPIRATION OF ALL KEY DOACS 34
5.4.1 INTRODUCTION 34
6 GLOBAL ANTICOAGULATION MARKET, BY DRUG CLASS 35
6.1 OVERVIEW 35
6.2 DOACS 36
6.3 WARFARIN 38
6.4 OTHER VITAMIN K 39
6.5 LMWH 40
7 GLOBAL ANTICOAGULATION MARKET, BY DISEASE INDICATION 41
7.1 OVERVIEW 41
7.2 HEART ATTACK 42
7.3 STROKE 42
7.4 DVT/PE 43
7.5 MHV 43
7.6 OTHERS 44
8 GLOBAL ANTICOAGULATION MARKET, BY ROA 45
8.1 OVERVIEW 45
8.2 ORAL 46
8.3 INJECTABLE 46
8.4 OTHERS 47
9 GLOBAL ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL 48
9.1 OVERVIEW 48
9.2 RETAIL PHARMACY 49
9.3 HOSPITAL PHARMACIES 49
9.4 ONLINE PHARMACIES 50
10 GLOBAL ANTICOAGULATION MARKET, BY REGION 51
10.1 OVERVIEW 51
10.2 NORTH AMERICA 53
10.2.1 US 55
10.2.2 CANADA 57
10.3 EUROPE 59
10.3.1 GERMANY 61
10.3.2 UK 63
10.3.3 FRANCE 65
10.3.4 ITALY 67
10.3.5 SPAIN 69
10.3.6 REST OF EUROPE 71
10.4 ASIA-PACIFIC 73
10.5 REST OF THE WORLD 86
11 COMPETITIVE LANDSCAPE 94
11.1 OVERVIEW 94
11.2 COMPETITIVE BENCHMARKING 95
11.3 GLOBAL ANTICOAGULATION MARKET: COMPANY RANKING 96
11.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 97
11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 97
11.5.1 NEW PRODUCT LAUNCHES 97
11.6 FINANCIAL MATRIX 98
12 COMPANY PROFILES 99
12.1 PFIZER, INC. 99
12.1.1 COMPANY OVERVIEW 99
12.1.2 FINANCIAL OVERVIEW 100
12.1.3 PRODUCTS/SERVICES OFFERED 100
12.1.4 KEY DEVELOPMENTS 100
12.1.5 SWOT ANALYSIS 101
12.1.6 KEY STRATEGIES 101
12.2 SANOFI 102
12.2.1 COMPANY OVERVIEW 102
12.2.2 FINANCIAL OVERVIEW 102
12.2.3 PRODUCTS/SERVICES OFFERED 103
12.2.4 KEY DEVELOPMENTS 103
12.2.5 SWOT ANALYSIS 103
12.2.6 KEY STRATEGIES 103
12.3 JOHNSON & JOHNSON SERVICES INC. 104
12.3.1 COMPANY OVERVIEW 104
12.3.2 FINANCIAL OVERVIEW 104
12.3.3 PRODUCTS/SERVICES OFFERED 105
12.3.4 KEY DEVELOPMENTS 105
12.3.5 SWOT ANALYSIS 105
12.3.6 KEY STRATEGIES 105
12.4 GLAXOSMITHKLINE PLC 106
12.4.1 COMPANY OVERVIEW 106
12.4.2 FINANCIAL OVERVIEW 106
12.4.3 PRODUCTS/SERVICES OFFERED 107
12.4.4 KEY DEVELOPMENTS 107
12.4.5 SWOT ANALYSIS 107
12.4.6 KEY STRATEGIES 107
12.5 DAIICHI SANKYO COMPANY, LIMITED 108
12.5.1 COMPANY OVERVIEWS 108
12.5.2 FINANCIAL OVERVIEW 108
12.5.3 PRODUCTS/SERVICES OFFERED 109
12.5.4 KEY DEVELOPMENTS 109
12.5.5 SWOT ANALYSIS 109
12.5.6 KEY STRATEGIES 110
12.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 111
12.6.1 COMPANY OVERVIEW 111
12.6.2 FINANCIAL OVERVIEW 112
12.6.3 PRODUCTS/SERVICES OFFERED 112
12.6.4 KEY DEVELOPMENTS 113
12.6.5 SWOT ANALYSIS 113
12.6.6 KEY STRATEGIES 113
12.7 BRISTOL-MYERS SQUIBB COMPANY 114
12.7.1 COMPANY OVERVIEW 114
12.7.2 FINANCIAL OVERVIEW 114
12.7.3 PRODUCTS/SERVICES OFFERED 115
12.7.4 KEY DEVELOPMENTS 115
12.7.5 SWOT ANALYSIS 115
12.7.6 KEY STRATEGIES 115
12.8 PORTOLA PHARMACEUTICALS, INC 116
12.8.1 COMPANY OVERVIEW 116
12.8.2 FINANCIAL OVERVIEW 116
12.8.3 PRODUCTS/SERVICES OFFERED 117
12.8.4 KEY DEVELOPMENTS 117
12.8.5 SWOT ANALYSIS 118
12.8.6 KEY STRATEGIES 118
12.9 NOVARTIS AG 119
12.9.1 COMPANY OVERVIEW 119
12.9.2 FINANCIAL OVERVIEW 119
12.9.3 PRODUCTS/SERVICES OFFERED 120
12.9.4 KEY DEVELOPMENTS 120
12.9.5 SWOT ANALYSIS 120
12.9.6 KEY STRATEGIES 120
12.10 F. HOFFMANN-LA ROCHE LTD 121
12.10.1 COMPANY OVERVIEW 121
12.10.2 FINANCIAL OVERVIEW 122
12.10.3 PRODUCTS/SERVICES OFFERED 122
12.10.4 KEY DEVELOPMENTS 122
12.10.5 SWOT ANALYSIS 123
12.10.6 KEY STRATEGIES 123
13 APPENDIX 124
13.1 REFERENCES 124
13.2 RELATED REPORTS 124
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19
TABLE 3 LIST OF KEY DOACS AND THEIR PATENT EXPIRATION 34
TABLE 4 GLOBAL: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 35
TABLE 5 GLOBAL: ANTICOAGULATION MARKET, BY DOACS, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 36
TABLE 6 GLOBAL: ANTICOAGULATION MARKET, FOR DOACS, BY TYPE, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 36
TABLE 7 GLOBAL: ANTICOAGULATION MARKET, FOR APIXABAN,BY DOACS 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 37
TABLE 8 GLOBAL: ANTICOAGULATION MARKET, FOR RIVAROXABAN,BY DOACS 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 37
TABLE 9 GLOBAL: ANTICOAGULATION MARKET, FOR EDOXABAN,BY DOACS 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 37
TABLE 10 GLOBAL: ANTICOAGULATION MARKET, FOR DABIGATRAN,BY DOACS 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 38
TABLE 11 GLOBAL: ANTICOAGULATION MARKET, FOR BETRIXABAN,BY DOACS 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 38
TABLE 12 GLOBAL: ANTICOAGULATION MARKET, FOR WARFARIN BY DRUG CLASS, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 39
TABLE 13 GLOBAL: ANTICOAGULATION MARKET, OTHER VITAMIN K, BY DRUG CLASS 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 39
TABLE 14 GLOBAL: ANTICOAGULATION MARKET, BY OTHER VITAMIN K, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 40
TABLE 15 GLOBAL: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 41
TABLE 16 GLOBAL: ANTICOAGULATION MARKET, FOR HEART ATTACK BY DISEASE INDICATION, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 42
TABLE 17 GLOBAL: ANTICOAGULATION MARKET, FOR STROKEBY DISEASE INDICATION, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 42
TABLE 18 GLOBAL: ANTICOAGULATION MARKET, FOR DVT/PEBY DISEASE INDICATION, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 43
TABLE 19 GLOBAL: ANTICOAGULATION MARKET, FOR DVT/PEBY DISEASE INDICATION, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 43
TABLE 20 GLOBAL: ANTICOAGULATION MARKET, FOR OTHERSBY DISEASE INDICATION, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 44
TABLE 21 GLOBAL: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 45
TABLE 22 GLOBAL: ANTICOAGULATION MARKET, FOR ORAL BY ROA, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 46
TABLE 23 GLOBAL: ANTICOAGULATION MARKET, FOR INJECTABLEBY ROA, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 46
TABLE 24 GLOBAL: ANTICOAGULATION MARKET, FOR OTHERSBY ROA, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 47
TABLE 25 GLOBAL: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 48
TABLE 26 GLOBAL: ANTICOAGULATION MARKET, FOR RETAIL PHARMACYBY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 49
TABLE 27 GLOBAL: ANTICOAGULATION MARKET, FOR MEDICAL STOREBY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 49
TABLE 28 GLOBAL: ANTICOAGULATION MARKET, FOR ONLINE PHARMACIESBY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION), BY REGION, 2022–2030 (USD MILLION) 50
TABLE 29 GLOBAL: ANTICOAGULATION MARKET, BY REGION, 2022–2030 (USD MILLION) 51
TABLE 30 NORTH AMERICA: ANTICOAGULATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 53
TABLE 31 NORTH AMERICA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 54
TABLE 32 NORTH AMERICA: ANTICOAGULATION MARKET, BY DOACS, 2022–2030 (USD MILLION) 54
TABLE 33 NORTH AMERICA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 54
TABLE 34 NORTH AMERICA: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 55
TABLE 35 NORTH AMERICA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 55
TABLE 36 US ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 55
TABLE 37 US: ANTICOAGULATION MARKET, BY DOACS, 2022–2030 (USD MILLION) 56
TABLE 38 US: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 56
TABLE 39 US: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 56
TABLE 40 US: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 57
TABLE 41 CANADA ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 57
TABLE 42 CANADA: ANTICOAGULATION MARKET, BY DOACS, 2022–2030 (USD MILLION) 57
TABLE 43 CANADA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 58
TABLE 44 CANADA: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 58
TABLE 45 CANADA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 58
TABLE 46 EUROPE: ANTICOAGULATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 59
TABLE 47 EUROPE: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 60
TABLE 48 EUROPE: ANTICOAGULATION MARKET, BY DOACS, 2022–2030 (USD MILLION) 60
TABLE 49 EUROPE: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 60
TABLE 50 EUROPE: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 61
TABLE 51 EUROPE: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 61
TABLE 52 GERMANY: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 61
TABLE 53 GERMANY: ANTICOAGULATION MARKET, BY DOACS, 2022–2030 (USD MILLION) 62
TABLE 54 GERMANY: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 62
TABLE 55 GERMANY: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 62
TABLE 56 GERMANY: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 63
TABLE 57 UK: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 63
TABLE 58 UK: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 63
TABLE 59 UK: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 64
TABLE 60 UK: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 64
TABLE 61 UK: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 64
TABLE 62 FRANCE: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 65
TABLE 63 FRANCE: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 65
TABLE 64 FRANCE: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 66
TABLE 65 FRANCE: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 66
TABLE 66 FRANCE: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 66
TABLE 67 ITALY: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 67
TABLE 68 ITALY: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 67
TABLE 69 ITALY: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 68
TABLE 70 ITALY: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 68
TABLE 71 ITALY: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 68
TABLE 72 SPAIN: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 69
TABLE 73 SPAIN: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 69
TABLE 74 SPAIN: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 70
TABLE 75 SPAIN: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 70
TABLE 76 SPAIN: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 70
TABLE 77 REST OF EUROPE: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 71
TABLE 78 REST OF EUROPE: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 71
TABLE 79 REST OF EUROPE: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 72
TABLE 80 REST OF EUROPE: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 72
TABLE 81 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 73
TABLE 82 ASIA-PACIFIC: ANTICOAGULATION MARKET SHARE, BY COUNTRY 2019 (%) 73
TABLE 83 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 74
TABLE 84 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 74
TABLE 85 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 74
TABLE 86 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 75
TABLE 87 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 75
TABLE 88 CHINA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 75
TABLE 89 CHINA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 76
TABLE 90 CHINA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 76
TABLE 91 CHINA: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 76
TABLE 92 CHINA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 77
TABLE 93 INDIA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 77
TABLE 94 INDIA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 77
TABLE 95 INDIA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 78
TABLE 96 INDIA: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 78
TABLE 97 INDIA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 78
TABLE 98 JAPAN: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 79
TABLE 99 JAPAN: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 79
TABLE 100 JAPAN: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 79
TABLE 101 JAPAN: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 80
TABLE 102 JAPAN: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 80
TABLE 103 AUSTRALIA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 80
TABLE 104 AUSTRALIA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 81
TABLE 105 AUSTRALIA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 81
TABLE 106 AUSTRALIA: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 81
TABLE 107 AUSTRALIA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 82
TABLE 108 SOUTH KOREA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 82
TABLE 109 SOUTH KOREA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 82
TABLE 110 SOUTH KOREA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 83
TABLE 111 SOUTH KOREA: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 83
TABLE 112 SOUTH KOREA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 83
TABLE 113 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 84
TABLE 114 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 84
TABLE 115 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 84
TABLE 116 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 85
TABLE 117 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 85
TABLE 118 REST OF THE WORLD: ANTICOAGULATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 86
TABLE 119 REST OF THE WORLD: ANTICOAGULATION MARKET SHARE, BY COUNTRY 2019 (%) 86
TABLE 120 REST OF THE WORLD: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 87
TABLE 121 REST OF THE WORLD: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 87
TABLE 122 REST OF THE WORLD: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 87
TABLE 123 REST OF THE WORLD: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 88
TABLE 124 REST OF THE WORLD: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 88
TABLE 125 MIDDLE EAST: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 88
TABLE 126 MIDDLE EAST: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 89
TABLE 127 MIDDLE EAST: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 89
TABLE 128 MIDDLE EAST: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 89
TABLE 129 MIDDLE EAST: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 90
TABLE 130 AFRICA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 90
TABLE 131 AFRICA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 90
TABLE 132 AFRICA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 91
TABLE 133 AFRICA: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 91
TABLE 134 AFRICA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 91
TABLE 135 LATIN AMERICA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2022–2030 (USD MILLION) 92
TABLE 136 LATIN AMERICA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2022–2030 (USD MILLION) 92
TABLE 137 LATIN AMERICA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 92
TABLE 138 LATIN AMERICA: ANTICOAGULATION MARKET, BY ROA, 2022–2030 (USD MILLION) 93
TABLE 139 LATIN AMERICA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION) 93
TABLE 140 MAJOR MANUFACTURERS RANKING, 2019 96
TABLE 141 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE ANTICOAGULATION MARKET 97
TABLE 142 NEW PRODUCT LAUNCHES 97
TABLE 143 PFIZER, INC: PRODUCTS/SERVICES OFFERED 100
TABLE 144 SANOFI: PRODUCTS/SERVICES OFFERED 103
TABLE 145 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS/SERVICES OFFERED 105
TABLE 146 JOHNSON & JOHNSON SERVICES INC: KEY DEVELOPMENTS 105
TABLE 147 GLAXOSMITH KLINE PLC: PRODUCTS/SERVICES OFFERED 107
TABLE 148 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS/SERVICES OFFERED 109
TABLE 149 DAIICHI SANKYO COMPANY, LIMITED: KEY DEVELOPMENTS 109
TABLE 150 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS/SERVICES OFFERED 112
TABLE 151 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY DEVELOPMENTS 113
TABLE 152 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED 115
TABLE 153 PORTOLA PHARMACEUTICALS, INC: PRODUCTS/SERVICES OFFERED 117
TABLE 154 PORTOLA PHARMACEUTICALS, INC: KEY DEVELOPMENTS 117
TABLE 155 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 120
TABLE 156 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 122
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS 14
FIGURE 2 ANTICOAGULATION MARKET STRUCTURE 15
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 21
FIGURE 4 MARKET DYNAMICS: ANTICOAGULATION MARKET 24
FIGURE 5 DRIVER IMPACT ANALYSIS 26
FIGURE 6 RESTRAINT IMPACT ANALYSIS 26
FIGURE 7 VALUE CHAIN ANALYSIS: ANTICOAGULATION MARKET 28
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: ANTICOAGULATION MARKET 30
FIGURE 9 GLOBAL ANTICOAGULATION MARKET, BY DRUG CLASS, 2019 & 2030 (USD MILLION) 35
FIGURE 10 GLOBAL: ANTICOAGULATION MARKET, USAGE, 2019 & 2030 (USD MILLION) 41
FIGURE 11 GLOBAL: ANTICOAGULATION MARKET, ROA, 2019 & 2030 (USD MILLION) 45
FIGURE 12 GLOBAL: ANTICOAGULATION MARKET, DISTRIBUTION CHANNEL, 2019 & 2030 (USD MILLION) 48
FIGURE 13 GLOBAL: ANTICOAGULATION MARKET, BY REGION 2019 & 2030 (USD MILLION) 51
FIGURE 14 GLOBAL: ANTICOAGULATION MARKET SHARE, BY REGION 2019 (%) 52
FIGURE 15 NORTH AMERICA: ANTICOAGULATION MARKET SHARE, BY COUNTRY 2019 (%) 53
FIGURE 16 EUROPE: ANTICOAGULATION MARKET SHARE, BY COUNTRY 2019 (%) 59
FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS 95
FIGURE 18 SALES & OPERATING INCOME, 2019 98
FIGURE 19 R&D EXPENDITURE, 2019 98
FIGURE 20 PFIZER, INC: FINANCIAL OVERVIEW SNAPSHOT 100
FIGURE 21 PFIZER, INC: SWOT ANALYSIS 101
FIGURE 22 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 102
FIGURE 23 SANOFI: SWOT ANALYSIS 103
FIGURE 24 JOHNSON & JOHNSON SERVICES INC.: FINANCIAL OVERVIEW SNAPSHOT 104
FIGURE 25 JOHNSON & JOHNSON SERVICES INC.: SWOT ANALYSIS 105
FIGURE 26 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 106
FIGURE 27 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 107
FIGURE 28 DAIICHI SANKYO COMPANY, LIMITED: FINANCIAL OVERVIEW SNAPSHOT 108
FIGURE 29 DAIICHI SANKYO COMPANY, LIMITED: SWOT ANALYSIS 109
FIGURE 30 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT 112
FIGURE 31 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SWOT ANALYSIS 113
FIGURE 32 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT 114
FIGURE 33 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS 115
FIGURE 34 PORTOLA PHARMACEUTICALS, INC: FINANCIAL OVERVIEW SNAPSHOT 116
FIGURE 35 PORTOLA PHARMACEUTICALS, INC: SWOT ANALYSIS 118
FIGURE 36 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 119
FIGURE 37 NOVARTIS AG: SWOT ANALYSIS 120
FIGURE 38 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 122
FIGURE 39 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 123
